Horizon Discovery grants a multi-product use license of its GS knockout CHO K1 cell line to NGM Bio
Cell line to be used to support research and development of biotherapeutics across therapeutic areas
21 Jan 2020
Horizon Discovery has announced that it will license its gene-edited Glutamine Synthetase (GS) knockout Chinese Hamster Ovary (CHO) K1 cell line to NGM Biopharmaceuticals, Inc. A clinical stage biopharmaceutical company based in South San Francisco, California, NGM is focused on developing novel therapeutics based on scientific understanding of key biological pathways underlying cardio-metabolic, liver, oncologic and ophthalmic diseases.
“We are pleased to enter into this licensing agreement with NGM for this GS knockout CHO K1 cell line to support its broad research and development efforts,” commented Dirk Gewert, Business Unit Director, Horizon Discovery. “Horizon aims to empower organizations of all sizes, from large pharmaceutical companies to clinical stage biotechs and early stage startups, to drive efficiencies in biotherapeutic manufacturing. To date, our complete CHO expression system has been licensed to over 50 companies globally, with a number of biotherapeutics expressed in these cells having progressed to investigational new drug (IND) filings.”
Horizon’s proprietary GS knockout CHO K1 cell line and protocols facilitate the development of stable cell lines for the expression of antibodies and other recombinant proteins. The Company also licenses a CHO expression system to pharmaceutical, biotechnology, and biosimilar companies, as well as contract manufacturing organizations. To enable companies to move from the DNA sequence of their potential biotherapeutic to clinical manufacturing as simply and rapidly as possible, the complete system includes the GS knockout CHO K1 cell line, a comprehensive package of supporting documentation, and an expression vector supplied under license from DNATwoPointO, Inc.
Want more of the latest science news straight to your inbox? Become a SelectScience member for free today>>
Related Products
Request Quote for All Products
CRISPR Screening Services
CRISPR Screening Services Horizon offers comprehensive CRISPR screening services from screen design and cell line selection to sophisticated bioinformatics analysis of the screen results. Our best-in-class CRISPR KO (knockout), CRISPRi (interference) and CRISPRa (activation) screening platforms can significantly advance our customers’ drug development programs by offering the highest quality and highest confidence in their screening results. Data analysis services, including sample preparation, Next-Gen Sequencing, and hit calling, can be provided for users of Edit-R Lentiviral sgRNA Pooled Screening Libraries. Simply provide whole cell pellets for each of your samples and we’ll do the rest. We can also help with the NGS data analysis and hit calling for data created using the Edit-R Pooled sgRNA Indexing PCR and Sequencing Primer Kits. Types of CRISPR Screen Expertise includes whole-genome and custom targeted drug resistance and sensitivity screens, synthetic lethality target discovery screens and complex phenotypic screens using a FACS-based readout. We have optimized 50+ cell lines for CRISPR screening and have completed over 300 screens to date. We offer a choice of CRISPR screen types depending on the expression effect you require: CRISPR KO screening with complete loss of gene expression provides the maximal window for phenotypic effect and high statistical power for hit discovery CRISPRi screening represses expression rather than completely knocking out the target gene and is ideally suited to study druggability and to evaluate the function of genes that when knocked-out are essential or that are amplified CRISPRa screening amplifies gene expression in its endogenous context and enables for the first time, to study activation-linked responses on a genome-wide level Dual CRISPRi & CRISPRa screening